Présentation de l'entreprise
XTL Biopharmaceuticals Ltd. operates as a biopharmaceutical entity focused on the acquisition and development of pharmaceutical drugs designed to treat autoimmune diseases within the Israeli market. The company functions specifically within the healthcare sector and the biotechnology industry, positioning itself to address significant therapeutic needs through the advancement of novel drug candidates. According to the latest available data, the company maintains a market capitalization of $5.54M, reports annual revenue of $968,000, and employs a workforce of 10 individuals. These valuation and revenue figures indicate that XTL Biopharmaceuticals Ltd. operates as a micro-cap entity with a relatively small scale, reflecting the typical characteristics of early-stage biotechnology firms that prioritize research and development over immediate profitability or extensive commercialization infrastructure.
Santé financière
The financial statements for the trailing twelve months show a revenue of $968,000 against a net income of $-6,308,000, while EBITDA data is not available. The substantial negative gap between the modest revenue figure and the significant net loss reveals a cost structure dominated by high operational expenses, likely driven by research and development activities and administrative costs inherent to the biotechnology sector. Free cash flow is not available for this period, which implies that the company's current financial flexibility is constrained by its cash burn rate rather than cash generation from operations. The gross margin stands at -232.9%, the operating margin at -853.6%, and the profit margin at 0.0%, indicating that the company is burning through capital at a rate that exceeds its revenue generation and is not yet achieving operational profitability. Regarding liquidity and leverage, the company holds $259,000 in cash while carrying $86,000 in debt, though the debt-to-equity ratio is not available for calculation. The current ratio is recorded at 0.70, which indicates that the company's current assets are insufficient to cover its current liabilities without external financing or asset liquidation. Return on Equity is reported at -577.1% and Return on Assets at -240.6%, metrics that reveal that management effectiveness in generating returns on shareholder and asset bases is currently negative due to the company's developmental stage and lack of earnings.
Évaluation de la valorisation
Trailing P/E and forward P/E ratios are not available for XTL Biopharmaceuticals Ltd. due to the lack of reported earnings over the trailing twelve months, which prevents a traditional earnings-based valuation comparison. The price-to-book ratio is not available, meaning there is no direct market premium or discount indicated relative to the company's book value based on the provided data. The price-to-sales ratio is 5.72, suggesting that the market values the company at nearly six times its annual revenue, while the EV/EBITDA multiple is not available, necessitating reliance on revenue-based metrics for valuation analysis. The stock has traded between a 52-week low of $2.12 and a 52-week high of $10.28, illustrating a wide trading range that reflects the high volatility typical of small-cap biotechnology stocks. The beta value is 0.68, indicating that the stock's price volatility is historically lower than the broader market benchmark, though this metric should be interpreted with caution given the company's micro-cap status and lack of earnings.
Growth & Income
Revenue growth and earnings growth rates are not available for the year-over-year period, which precludes an analysis of whether earnings are growing faster or slower than revenue. The company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the company reinvests all available earnings, or in this case, capital reserves, back into its research and development pipeline rather than distributing income to shareholders. Since the company is not a dividend payer, the growth profile is entirely dependent on the successful advancement of its lead drug candidate, hCDR1, and the eventual commercialization of its pharmaceutical assets. The overall growth and income profile is characterized by a lack of current profitability, no cash returns to shareholders, and a reliance on future drug approvals to transform the current negative financial metrics into sustainable growth and positive cash flows.